Trial Profile
BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Sponsors BIOTRONIK
- 12 Dec 2017 Planned End Date changed from 1 Aug 2020 to 1 Sep 2021.
- 12 Dec 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 28 Oct 2014 New trial record